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Abstract: BACKGROUND An incidental lesion of the parasympathetic ganglia during circumferential
pulmonary vein isolation (CPVI) may affect heart rate variability (HRV). AIMS We studied the pattern of
changes in HRV parameters and the relationship between the 1‑year HRV change following CPVI and the
recurrence of atrial fibrillation (AF). METHODS A total of 100 consecutive patients undergoing CPVI
for paroxysmal AF were enrolled (mean [SD] age, 56 [11.2] years; 61 men). We measured HRV on the
day before and after CPVI, and then at 1 month as well as 3, 6, and 12 months after CPVI using 24‑hour
Holter monitoring. RESULTS During the median follow‑up of 33 months, 38 patients experienced the
late recurrence of AF (LRAF). Compared with the pre‑CPVI values, HRV was significantly attenuated
on day 1 after CPVI in all patients. However, at 3 to 6 months after CPVI, all HRV parameters
remained significantly decreased in LRAF‑free patients but not in those with LRAF. The multivariate
Cox analysis showed that early AF recurrence within the blanking period (hazard ratio [HR], 4.87; 95%
CI, 2.44–9.69; P <0.001) and a change in the standard deviation of normal‑to‑normal intervals (SDNN)
observed 3 months after ablation (HR, 0.99; 95% CI, 0.98–1; P = 0.01) were associated with LRAF. The
cumulative LRAF freedom after CPVI was greater in patients with an SDNN reduction of more than
25 ms reported 3 months after ablation than in those with a reduction of 25 ms or lower (log‑rank P
= 0.004). CONCLUSIONS Sustained parasympathetic denervation during 12 months after CPVI was a
marker of successful CPVI, whereas a 3‑month post‑CPVI SDNN reduction of 25 ms or lower predicted
LRAF.
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patients with AF undergoing CA for the first 
time.2
The CPVI procedure may affect the cardiac au‑
tonomic nervous activity through (un)intention‑
al injury of the left atrial (LA) parasympathetic 
ganglia (ganglionated plexi [GP]) in the proxim‑
ity of the PVs by radiofrequency (RF) current.1,3 
INTRODUCTION Autonomic nervous system 
significantly modulates the triggers for atrial 
fibrillation (AF) within the pulmonary veins 
(PVs).1 Circumferential pulmonary vein isola‑
tion (CPVI) is the mainstay of catheter abla‑
tion (CA) for paroxysmal AF (PAF); however, 



















BACKGROUND An incidental lesion of the parasympathetic ganglia during circumferential pulmonary 
vein isolation (CPVI) may affect heart rate variability (HRV).
AIMS We studied the pattern of changes in HRV parameters and the relationship between the 1‑year 
HRV change following CPVI and the recurrence of atrial fibrillation (AF).
METHODS A total of 100 consecutive patients undergoing CPVI for paroxysmal AF were enrolled (mean 
[SD] age, 56 [11.2] years; 61 men). We measured HRV on the day before and after CPVI, and then at 1 month 
as well as 3, 6, and 12 months after CPVI using 24‑hour Holter monitoring.
RESULTS During the median follow ‑up of 33 months, 38 patients experienced the late recurrence of AF 
(LRAF). Compared with the pre ‑CPVI values, HRV was significantly attenuated on day 1 after CPVI in all 
patients. However, at 3 to 6 months after CPVI, all HRV parameters remained significantly decreased in 
LRAF ‑free patients but not in those with LRAF. The multivariate Cox analysis showed that early AF recurrence 
within the blanking period (hazard ratio [HR], 4.87; 95% CI, 2.44–9.69; P <0.001) and a change in 
the standard deviation of normal ‑to ‑normal intervals (SDNN) observed 3 months after ablation (HR, 0.99; 
95% CI, 0.98–1; P = 0.01) were associated with LRAF. The cumulative LRAF freedom after CPVI was greater 
in patients with an SDNN reduction of more than 25 ms reported 3 months after ablation than in those 
with a reduction of 25 ms or lower (log ‑rank P = 0.004).
CONCLUSIONS Sustained parasympathetic denervation during 12 months after CPVI was a marker 
of successful CPVI, whereas a 3‑month post ‑CPVI SDNN reduction of 25 ms or lower predicted LRAF.
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exercise testing, and 24‑hour Holter monitoring. 
The study was approved by the institutional eth‑
ics committee, and all patients signed informed 
consent to participate in the study.
Ablation procedure The CPVI procedure in 
our hospital was described in detail elsewhere.9 
Briefly, after transseptal puncture, a 3‑dimen‑
sional map was created by the electroanatomic 
mapping system (EnSite Velocity, St. Jude, Min‑
neapolis, Minnesota, United States) and thereaf‑
ter fused with the segmented computed tomog‑
raphy model of the LA. The RF current was ap‑
plied via an externally irrigated 4‑mm tip cath‑
eter (Therapy Cool ‑Flex, St. Jude), with a pow‑
er of 30 W and a flow rate of 17 ml/min. Local 
RF delivery was continued only until a reduc‑
tion of atrial potential amplitude greater than 
80% was achieved or for a maximum of 30 to 
40 seconds and 40 to 60 seconds at the poste‑
rior and anterior LA wall, respectively, which‑
ever came first. Ipsilateral PVs (left and right) 
were encircled in pairs with a circumferential 
ablation line deployed 5 mm from the ante‑
rior and 15 to 20 mm from the posterior as‑
pects of their ostia, respectively. During abla‑
tion, the electrical activity of PVs was evaluat‑
ed with a circumferential mapping catheter.9 In 
patients with a history of typical atrial flutter, 
ablation of the cavotricuspid isthmus was per‑
formed during the same session.2
Postablation follow ‑up We routinely admin‑
istered AADs during the 3‑month blanking peri‑
od2 and thereafter discontinued them in all pa‑
tients. Postablation follow ‑up visits were sched‑
uled at 1 month, 3 months, 6 months, and ev‑
ery 6 months afterwards. They included phys‑
ical examination, 12‑lead electrocardiography, 
and 24‑hour Holter monitoring. The recurrence 
of AF was defined as any symptomatic or asymp‑
tomatic AF or atrial tachycardia (AT) episode 
longer than 30 seconds.2 The early recurrence 
of AF (ERAF) was defined as atrial arrhythmia 
recurring within the 3‑month blanking period 
after CA, whereas the recurrence of arrhythmia 
3 months after CA was considered the late re‑
currence of AF (LRAF).2 Patients experiencing 
ERAF during the blanking period were treat‑
ed by cardioversion or rate control (but with‑
out early reablation), and those with LRAF af‑
ter the blanking period were offered AAD read‑
ministration or repeat CA.2
Analysis of heart rate variability In all pa‑
tients, serial 3‑channel 24‑hour Holter record‑
ings (Del Mar Reynolds Medical, Inc., Irvine, 
California, United States) were obtained for 
HRV analysis with the Impresario software 
(Del Mar Reynolds Medical, Inc.) 1 day prior 
to ablation as well as 1 day, 1 month, 3 months, 
and 6 months after the procedure, and every 
The LA denervation is reported to significant‑
ly reduce the AF recurrence rate after CPVI.2,4,5 
However, in the months following CA, the pro‑
cesses of healing and reinnervation ensue, po‑
tentially influencing the procedure outcome.3,6,7 
A long ‑term pattern of CA ‑related cardiac dener‑
vation (and subsequent reinnervation) is under‑
reported and currently available data are conflict‑
ing.3,6-8 We studied the pattern of longitudinal 
changes in heart rate variability (HRV; as a mea‑
sure of cardiac denervation) after CPVI for PAF as 
well as the relationship between the post ‑CPVI 
change in HRV and long ‑term freedom from AF.
METHODS Study population Patient selec‑
tion for this prospective single ‑center study is 
presented in Supplementary material, Figure S1. 
Of the 294 consecutive patients who underwent 
445 RF ‑CA procedures for symptomatic and drug‑
‑resistant AF in the Clinical Centre of Serbia be‑
tween 2013 and 2016, we excluded those after ab‑
lation for persistent AF, repeat ablation for AF, 
and / or substrate ‑based ablation for AF (n = 195); 
those with a history of slow pathway or septal ac‑
cessory pathway ablation and / or pacemaker im‑
plantation (n = 23); those with a history of heart 
failure, myocardial infarction (MI), and / or diabe‑
tes mellitus (n = 69); those with more than 20% 
of the 24‑hour Holter monitoring time spent in 
AF, frequent atrial and / or ventricular prema‑
ture beats or artifacts (n = 49); and those with 
12 months or less of post ‑CA follow ‑up (n = 9).
The study group included 100 patients with 
PAF with no significant structural heart disease 
who underwent their first CA for AF with CPVI 
stand ‑alone ablation strategy and were followed 
for more than 12 months after the procedure. 
We defined PAF as an AF episode lasting longer 
than 30 seconds but shorter than 7 days.2 All 
antiarrhythmic drugs (AADs) were discontin‑
ued at least 5 half ‑lives before CA (amiodarone 
was ceased more than 3 months prior to CA). Be‑
fore the procedure, all patients underwent trans‑
thoracic echocardiography, cardiopulmonary 
WHAT’S NEW?
Circumferential pulmonary vein isolation may affect the cardiac autonomic 
nervous activity through an incidental lesion of the left atrial parasympathetic 
ganglia. Currently available data on the long ‑term pattern of ablation ‑related 
cardiac denervation and impact on the ablation outcome are conflicting. In our 
study, we observed a characteristic square root pattern of the longitudinal 
change in heart rate parameters in the first year after ablation. The change in 
heart rate variability, indicating a significant parasympathetic denervation, 
persisted throughout the first 12 months after the procedure in arrhythmia‑
‑free patients. The parameters returned to baseline values in patients with 
a relapse. A multivariable analysis showed that a reduced standard deviation 
of normal ‑to ‑normal intervals at the end of the 3‑month postablation blanking 
period (by more than 25 ms compared with the preablation value) was 
significantly associated with long ‑term freedom from atrial fibrillation.
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42 patients. Three major complications (ingui‑
nal hematoma, retroperitoneal hematoma, and 
coronary artery air embolism) occurred in 3 pa‑
tients but did not impede the completion of CPVI.
The ERAF was reported in 15 patients (PAF in 
7 patients, paroxysmal AT in 6, and persistent 
AT in 2). During the 3‑month blanking period, 
the following drugs were prescribed: propafe‑
none (to 68 patients), amiodarone (22), sotalol 
(7), a β ‑blocker (1), and verapamil (1); 1 patient 
was taken off AADs due to bradycardia.
During the median post ‑CA follow ‑up of 
33 months (IQR, 21–40 months), a total of 38 
patients developed LRAF (PAF was present in 
27 patients, paroxysmal AT in 9, and persistent 
AT in 2). In 17 patients, LRAF was noted between 
3 and 12 months after CA, whereas in the re‑
maining 21 patients, the recurrence of arrhyth‑
mia was observed later than 12 months after CA. 
During the first year after CA, in 16 of the 17 
patients with LRAF, AADs were reinstituted as 
monotherapy with propafenone (n = 1), sotalol 
(n = 1), verapamil (n = 1), or a β ‑blocker (n = 5), or 
as a combination of amiodarone and a β ‑blocker 
(n = 3) or propafenone and a β ‑blocker (n = 5). 
The remaining asymptomatic patient continued 
without AADs. The CA procedure was repeated 
in 18 of the 38 patients with LRAF after a mean 
(SD) time of 16 (7) months. At repeat CA, PV re‑
connections were identified in 16 of the 18 pa‑
tients (89%) with a mean (SD) number of 2.4 (0.9) 
reconnected PVs per patient. The PV reconnec‑
tion rates (per patient) were as follows: left su‑
perior PV, 10/18 (56%); left inferior PV, 7/18 
(39%); right superior PV, 11/18 (61%); and right 
inferior PV, 10/18 (56%).
No new adverse cardiovascular events such 
as sudden death, acute coronary syndrome, or 
cardiac decompensation were observed during 
the follow ‑up.
Changes in heart rate variability parameters 
at 1 year after ablation There were no signif‑
icant differences in HRV parameters at baseline 
(before CA) in patients with LRAF after CA and 
those without, except for SDNN (median, 117 ms 
[IQR, 99–145 ms] vs 141 ms [IQR, 108–201 ms]; 
P = 0.04; TABLE 2).
The longitudinal changes in HRV at 1 year 
after ablation are summarized in TABLE 2 and 
FIGURES 1 and 2. There was a significant decrease 
in SDNN, rMSSD, SDSD, HRV index, mean R ‑R 
interval, pNN50, and LF / HF ratio, as well as 
a significant increase in the mean HR after CA 
compared with the preablation values, both in 
patients with LRAF (all P <0.001) and those 
without (all P <0.001; except for changes in 
SDSD and the LF / HF ratio with a P value of 
0.02 and 0.002, respectively). In all patients 
(ie, those with and without LRAF), the post 
hoc analysis showed a  significant attenua‑
tion of all HRV parameters on the first day 
6 months thereafter. To provide high ‑quality 
HRV measurements, all patients with any AF 
episodes on Holter recordings, ventricular 
and / or atrial premature beats, and / or arti‑
facts lasting more than 20% of the recording 
time were excluded from further analysis.10 
The following HRV time parameters were an‑
alyzed: the standard deviation of normal ‑to‑
‑normal (NN) intervals (SDNN; ms), the root 
mean square of the differences between adja‑
cent NN intervals (rMSSD; ms), the standard 
deviation of differences between adjacent NN 
intervals (SDSD; ms), the HRV index (the inte‑
gral of the density of the R ‑R interval histogram 
divided by its height), mean R ‑R interval (ms), 
mean heart rate (HR; bpm), and the percent‑
age of adjacent NN interval differences greater 
than 50 ms (pNN50; %).10 The HRV frequency 
measures were calculated with the fast Fourier 
transform for each 5‑minute segment of data 
with the low‑ to high ‑frequency (LF / HF) ratio.10
Statistical analysis Continuous variables 
with normal distribution were presented as 
mean (SD), and those with asymmetrical distri‑
bution, as median and interquartile range (IQR; 
first quartile, third quartile [Q1–Q3]). Categor‑
ical variables were presented as percentages. 
Continuous variables were compared by the in‑
dependent sample t test or the Mann–Whitney 
test, as appropriate, while the χ2 test and Fish‑
er test were used to compare proportions. Con‑
tinuous variables (the HRV parameters) with 
repeated measures (successive Holter record‑
ings) were analyzed with the Friedman test, 
and then the post hoc analysis was conduct‑
ed using the Wilcoxon test with the Bonfer‑
roni correction. Risk factors for LRAF were 
evaluated using the univariate and multivar‑
iate Cox regression analyses. The cutoff val‑
ue of continuous variables significantly asso‑
ciated with LRAF was determined by the re‑
ceiver operating characteristic curve analysis. 
The LRAF ‑free survival rates were compared 
using the Kaplan–Meier analysis with the log‑
‑rank test. A 2‑sided P value of less than 0.05 
was considered significant. All analyses were 
performed with the SPSS software, version 21.0 
(IBM Corp., Armonk, New York, United States).
RESULTS Study population The study group 
included 100 patients (mean [SD] age, 56 [11.2] 
years; 61 men). Baseline clinical characteristics 
are presented in TABLE 1.
The mean (SD) left and right CPVI ablation 
line was 116 (19) mm and 119 (22) mm long, re‑
spectively. The CPVI was successfully complet‑
ed in all patients with the mean (SD) RF deliv‑
ery time for left and right PV isolation of 29.1 
(14.6) min and 31.2 (14.4) min, respectively. Ab‑
lation of typical atrial flutter was performed in 
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and increased, respectively (compared with 
the preablation values) at 1 year after CA. How‑
ever, in LRAF ‑free patients, all HRV parame‑
ters (except the LF / HF ratio) remained signifi‑
cantly changed on serial Holter recordings dur‑
ing the first year after the procedure, as pre‑
sented in TABLE 2 and FIGURES 1 and 2.
The comparison of changes in the HRV param‑
eters during the first year after CA between pa‑
tients with and without LRAF is shown in TABLE 3. 
The  postablation reduction of  several HRV 
after ablation compared with the  preabla‑
tion values, with subsequent gradual return 
to the baseline values. In patients with LRAF, 
the postablation values of rMSSD, SDSD, HRV 
index, pNN50, LF / HF ratio, and SDNN re‑
turned to the values similar to baseline (rMS‑
SD and SDSD at 1 month; HRV index, pNN50, 
and LF / HF ratio at the Holter recording at 3 
months after CA; and SDNN at 6 months af‑
ter CA), whereas the mean R ‑R interval and 
mean HR remained significantly reduced 
TABLE 1 Baseline clinical characteristics of the study population
Variable All patients 
(n = 100)
Patients with 
LRAF (n = 38)
Patients without 
LRAF (n = 62)
P value
Age, y, mean (SD) 56.0 (11.2) 57.5 (9.5) 55.1 (12.1) 0.29
Male sex 61 (61) 23 (60.5) 38 (61.3) 0.94
BMI, kg/m2, mean (SD) 27.1 (4.2) 27.1 (4.6) 27.1 (3.5) 0.99
Years since first ‑diagnosed AF, median (IQR) 4 (2–9) 3 (2–7.3) 5 (2.5–9.5) 0.28
Duration of an AF episode (>48 h) 21 (21) 11 (28.9) 10 (16.1) 0.13
LVEDD, mm, mean (SD) 51.9 (4) 52.0 (4.5) 51.8 (3.7) 0.87
LVEF, %, mean (SD) 62.2 (6.5) 60.7 (7.7) 63.1 (5.5) 0.08
LA diameter, mm, mean (SD) 39.4 (5.2) 39.0 (5.6) 39.7 (4.9) 0.54
CAD (with no history of MI) 3 (3) 3 (7.9) 0 0.05
Hypertension 49 (49) 19 (50) 30 (48.4) 0.88
Chronic pulmonary disease 2 (2) 2 (5.3) 0 0.14
History of stroke 9 (9) 1 (2.6) 8 (12.9) 0.15
History of hyperthyroidism 9 (9) 2 (5.3) 7 (11.3) 0.48
CHA2DS2‑VASc score, mean (SD) 1.5 (1.4) 1.3 (1.1) 1.6 (1.5) 0.37
HATCH score, mean (SD) 0.7 (0.8) 0.6 (0.8) 0.8 (0.9) 0.41
Patients with complete PVI 100 (100) 38 (100) 62 (100) >0.99
Cavotricuspid isthmus ablation 42 (42) 11 (29.7) 31 (50) 0.048
Fluoroscopy time, min, mean (SD) 29.7 (14.4) 33.2 (16) 27.7 (13.1) 0.07
RF delivery time, min, mean (SD) 64.2 (29.2) 67.1 (32.5) 62.5 (27.3) 0.46
Ineffective AADs, mean (SD) 2.6 (1.3) 2.5 (1.3) 2.6 (1.3) 0.72
Amiodarone 58 (58) 24 (63.2) 34 (54.8) 0.41
β ‑Blocker 65 (65) 24 (63.2) 41 (66.1) 0.76
ACEIs / ARBs 39 (39) 28 (73.7) 11 (17.7) <0.001
Statins 22 (22) 10 (26.3) 12 (19.7) 0.44
eGFR, ml/min/1.73 m2, mean (SD) 104.1 (33) 107.3 (31.4) 106.7 (34.7) 0.52
CRP after ablation, mg/l, median (IQR) 9.7 (6.5–16.9) 10.1 (6.6–18.5) 9.6 (5.9–14.1) 0.47
ERAF 15 (15) 13 (34.2) 2 (3.2) <0.001
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: AADs, antiarrhythmic drugs; ACEI, angiotensin ‑converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin 
receptor blocker; BMI, body mass index; CAD, coronary artery disease; CHA2DS2‑VASc, congestive heart failure, hypertension, age ≥75 
years, diabetes mellitus, history of stroke or thromboembolism, vascular disease, age 65 to 74 years, female sex; CRP, C ‑reactive 
protein; eGFR, estimated glomerular filtration rate; ERAF, early recurrence of atrial fibrillation; HATCH, hypertension, age, stroke or 
transient ischemic attack, chronic obstructive pulmonary disease, heart failure; IQR, interquartile range; LA, left atrial; LRAF, late 
recurrence of atrial fibrillation; LVEDD, left ventricular end ‑diastolic dimension; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; PVI, pulmonary vein isolation; RF, radiofrequency
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LRAF and the following variables: ablation for 
the cavotricuspid isthmus, ERAF, pre‑CA SDNN, 
Δ SDNN at 1 day, 1 month, and 3 months post‑
CA, Δ rMSDD at 3 months post‑CA, and Δ SDSD 
at 1 day post‑CA (all P <0.05). However, on mul‑
tivariate analysis, only ERAF (hazard ratio [HR], 
4.87; 95% CI, 2.44–9.69; P <0.001) and Δ SDNN 
at 3 months post‑CA (HR, 0.99; 95% CI, 0.98–
1; P = 0.01) were independently associated with 
the late arrhythmia relapse (see Supplementa‑
ry material, Table S1).
The  reduction of Δ SDNN at 3 months 
post‑CAshowed a predictive value for LRAF 
(area under the receiver operating character‑
istic curve, 0.63; 95% CI, 0.52–0.74; P = 0.03). 
The cutoff value of 25 ms or lower for Δ SDNN 
at 3 months post‑CA had the best predictive 
ability for LRAF (HR, 2.52; 95% CI, 1.30–4.89; 
P = 0.01) with a sensitivity and specificity 
of 62.9% and 63.2%, respectively. The  Ka‑
plan–Meyer cumulative probability of post‑
‑CA LRAF ‑freedom was significantly high‑
er in patients with a reduction in Δ SDNN 
at 3 months post‑CA
 
higher than 25 ms than 
in those with a reduction of 25 ms or lower 
(log ‑rank P = 0.004) (FIGURE 3).
parameters (ie, Δ SDNN, Δ rMSSD, Δ SDSD, and 
Δ pNN50) was significantly greater in the LRAF‑
‑free patients compared with those with LRAF 
on the first postablation day, and a significant 
difference in these HRV parameters between 
both groups was mostly preserved at 1 month 
as well as at 3, 6, and 12 months after the proce‑
dure (TABLE 3). There were no significant differenc‑
es in the postablation changes in other HRV pa‑
rameters (ie, Δ HRV index, Δ mean R ‑R interval, 
Δ mean HR, and Δ LF / HF ratio) during the first 
year after CA between patients with LRAF and 
those without.
In patients with LRAF (n = 38), there was no dif‑
ference in the change of the HRV parameters be‑
tween patients who underwent the redo ‑CA proce‑
dure and those who were treated only with AADs 
(median SDNN before CA, 113 ms [IQR, 95–150 ms] 
vs 122 ms [IQR, 102–143 ms], P = 0.5; reduction 
in the median SDNN at 3 months after CA, 5 ms 
[IQR, –5 to 38 ms] vs 21 ms [2–46 ms], P = 0.23).
Risk factors for the late recurrence of atri‑
al fibrillation The univariate Cox analysis in‑
cluded all variables listed in TABLES 1–3. It showed 
a significant univariate association between 
FIGURE 1 Box ‑and ‑whisker plots illustrating the square root pattern of changes in heart rate variability (HRV) observed on 24‑hour Holter recordings during 
the first year after catheter ablation (CA): A – standard deviation of normal ‑to ‑normal intervals (SDNN); B – root mean square of the differences between adjacent 
normal ‑to ‑normal intervals (rMSSD); C – standard deviation of differences between adjacent normal ‑to ‑normal intervals (SDSD); D – HRV index. The P value was 
considered significant according to the Bonferroni correction for the post hoc analysis. Grey asterisks represent the significant P value for the post hoc analysis 
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71.4% to 100% in those who experienced ERAF 
(n = 15) (Supplementary material, Figure S2).
DISCUSSION Our study of 100 patients with 
PAF with no significant structural heart dis‑
ease showed a square root pattern of longitu‑
dinal change in the HRV parameters during 
the first year after CPVI, with an immediate 
postablation change in HRV indicating a sig‑
nificant parasympathetic attenuation and sub‑
sequent (partial) gradual return of the HRV in‑
dices in the following months toward preab‑
lation levels. The HRV markers of a signifi‑
cant reduction in parasympathetic tone per‑
sisted throughout the next 12 months after 
the procedure in the arrhythmia ‑free patients. 
In patients with LRAF, the HRV parameters re‑
turned to baseline values within 3 to 6 months 
after CPVI. The change in SDNN at the end 
of the 3‑month post ‑CPVI blanking period 
was significantly associated with long ‑term 
AF recurrence.
Autonomic nervous system and atrial fi‑
brillation The LA contains 4 GPs, which are 
located at the epicardial aspect of the LA–PV 
junction.1 The GPs include both adrenergic and 
cholinergic nerve fibers that control cardiac 
A reduction of 25 ms or lower for Δ SDNN 
at 3 months post‑CA
 
was associated with an in‑
crease in the prevalence of LRAF from 19.6% to 








SDNN reduction at 3 months >25 ms
SDNN reduction at 3 months ≤25 ms
Log‑rank P = 0.004
Follow‑up after ablation, mo

















in relation to the change in the standard deviation of normal ‑to ‑normal intervals (SDNN) 

















































































































FIGURE 2 Box ‑and ‑whisker plots depicting the square root pattern of changes in heart rate variability (HRV) observed on 24‑hour Holter recordings during 
the first year after catheter ablation (CA): A – mean R ‑R interval; B – mean heart rate (HR); C – percentage of adjacent normal ‑to ‑normal interval differences greater 
than 50 ms (pNN50); D – low‑ to high ‑frequency (LF / HF) ratio. The P value was considered significant according to the Bonferroni correction for the post hoc 
analysis. Grey asterisks represent the significant P value for the post hoc analysis in patients without the late recurrence of atrial fbrillation (LRAF). Red asterisks 
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denervation after CA and subsequent gradual 
reinnervation. Of note, despite partial rein‑
nervation after 3 to 6 months after ablation, 
the HRV markers of the overall sympatho ‑vagal 
balance (SDNN, SDSD, pNN50, and mean R ‑R 
interval) and more specific HRV indices of para‑
sympathetic activity (rMSSD and LF / HF ratio) 
were still significantly reduced at 1 year after 
CPVI in the AF ‑free patients but not in those 
with the recurrence of arrhythmia. Thus, in 
otherwise mostly healthy patients, persistent‑
ly reduced HRV after CPVI for PAF is a mark‑
er of better long ‑term AF control. However, 
since reduced HRV was previously recognized 
as a marker of adverse cardiovascular outcome 
in patients with a history of MI, heart failure, or 
diabetes,14 it is questionable whether the post‑
‑CPVI denervation may affect the prognosis of 
patients undergoing ablation for AF if they de‑
velop significant cardiometabolic comorbidities 
in the future. Importantly, our study patients 
with the median postablation follow ‑up of al‑
most 3 years were free of new adverse cardio‑
vascular events, such as sudden death, MI, or 
heart failure.
Predicting circumferential pulmonary vein 
isolation outcome with the periprocedural 
assessment of changes in heart rate vari‑
ability Previous studies identified changes in 
HRV occurring immediately after CPVI as a pre‑
dictor of AF recurrence.3,6 -8,12,13,15 Thus, postabla‑
tion findings of high HF and a low LF / HF ratio 
or that changed by more than 0.26 were all in‑
dependently associated with LRAF.6,7 However, 
interpreting changes in the HRV frequency pa‑
rameters (ie, HF and LF) is limited because their 
assessment depends considerably on respira‑
tion and measurement conditions.10 On the oth‑
er hand, the measurement of time ‑domain HRV 
parameters is more stable and reproducible in 
routine practice.10 The absolute value of SDNN 
at 3 months after CPVI was previously iden‑
tified as an independent risk factor for an AF 
relapse.8 However, our study further under‑
lines the utility of the periprocedural SDNN 
analysis. First, we show that the PAF patients 
with higher preablation SDNN (as a measure of 
overall HRV) are the best candidates for CPVI. 
In addition, the SDNN reduction of 25 ms or 
lower at 3 months after CPVI was associated 
with a 2.5‑fold increase in the probability of 
LRAF. Data on Δ SDNN at 3 months post‑CA 
are usually easily available on a routine follow‑
‑up Holter recording and may distinguish be‑
tween the ERAF patients at increased and low 
risk for subsequent LRAF. Although ERAF is 
one of the strongest predictors of LRAF, later 
AF episodes gradually subside with a resolu‑
tion of CA ‑related LA inflammation in approx‑
imately 40% to 60% of patients with ERAF.2 
The reliable prediction of the long ‑term CPVI 
impulse formation and propagation, and there‑
fore modulate the interplay between the PV 
triggers and LA substrate.6 Thus, in younger 
patients with no evidence of structural heart 
disease, vagal predominance promotes the trig‑
gered PV activity associated with afterdepo‑
larization, shortens the PV refractoriness and 
AF cycle length, resulting in the inducibility 
and / or maintenance of AF.1,11
Outcomes of denervation and ablation for 
atrial fibrillation The GP ablation led to a va‑
gal response (ie, bradycardia and hypotension) 
during RF current application, and subsequent‑
ly to noninducibility of vagally mediated AF.1 
Several studies reported a significant change of 
the HRV parameters after CPVI, indicating a re‑
markable parasympathetic withdrawal.3,6 -8,12,13 
The GPs in the LA are located close to the select‑
ed CPVI ablation trajectory1 and, therefore, are 
commonly collaterally damaged during the ab‑
lation.3,6 -8,12,13 Clinical studies showed a signif‑
icantly higher number of cases free of AF af‑
ter CPVI in patients who exhibited a more pro‑
nounced postablation change in the HRV in‑
dices of parasympathetic denervation.3,6,7,12,13 
Consequently, the GPs in the LA became an im‑
portant adjuvant ablation target on top of CPVI, 
significantly improving the long ‑term CPVI out‑
come.4,5 Moreover, parasympathetic attenuation 
after the procedure had a supplemental and dis‑
tinct effect on freedom from AF, irrespective of 
the late PV reconnection.7 However, healing of 
an RF ‑induced injury in the following weeks may 
be accompanied with reinnervation at the LA–PV 
junction, potentially influencing the long ‑term 
outcome after CPVI.3,7,12,13 
Interestingly, the follow ‑up studies on per‑
sistency of denervation after AF ablation re‑
ported conflicting findings.3,6 -8,12,13 Initially, it 
was suggested that post ‑CPVI denervation per‑
formed with a conventional RF catheter is only 
a transient state followed by complete reinner‑
vation at 6 months after ablation.3,8 However, 
a more recent study reported more persistent 
HRV changes during the first year after CPVI 
performed with more powerful irrigated RF abla‑
tion.6 Again, the HRV reduction during the first 
year after CPVI was significantly more striking 
and persistent in the AF ‑free patients than in 
those with recurrent AF.6 In addition, the long‑
‑term HRV change after CPVI was consider‑
ably different between patients with PAF and 
those without.6
Our study included a homogenous cohort 
of PAF patients with no significant structur‑
al heart disease who underwent stand ‑alone 
CPVI conducted with the use of irrigated RF 
catheters. The longitudinal change in the HRV 
parameters during the first year after CPVI 
depicted a characteristic square root pattern, 
consisting of significant early parasympathetic 
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success may optimize the selection of appro‑
priate rhythm monitoring strategy, AADs use, 
and anticoagulant treatment following CA.16
Study limitations Intermittent rhythm mon‑
itoring strategy with a 24‑hour Holter recording 
probably underestimated the AF recurrence rate 
after CPVI.2 In all patients, AADs were routine‑
ly prescribed during the blanking period, which 
possibly affected the HRV parameters after CA.10 
However, our postablation strategy conformed 
with the current guidelines.2
The study population included highly select‑
ed, relatively young, and healthy patients with 
PAF. Approximately 50% of the patients were 
hypertensive and 5% had stable coronary ar‑
tery disease, but patients with diabetes, a his‑
tory of MI, and / or heart failure were excluded. 
Thus, the transferability of our research results 
to the general AF population undergoing CA is 
limited. In our view, notwithstanding the fact 
that strictly including only those with lone 
PAF would provide straightforward informa‑
tion, such patient selection minimized the influ‑
ence of cardiovascular disease(s) on the HRV pa‑
rameters and their changes in the first months 
after ablation.
The exclusion of patients whose follow ‑up 
Holter recordings showed frequent aberrant 
beats might have introduced a selection bias. 
However, such an approach ensured a good qual‑
ity of HRV measurements.10 The HRV analysis 
was limited to 12 months after CPVI, whereas 
the reinnervation could have continued beyond 
the first year after ablation.
The association between changes in HRV and 
freedom from AF after CA may not necessari‑
ly be a causal relationship. Persistent chang‑
es in autonomic tone may be simply the result 
of a more effective (ie, transmural) RF lesion, 
a durable ablation line, and therefore a better 
CA outcome.
Conclusions Our study identified a square root 
pattern of changes in the HRV parameters dur‑
ing the first year after CPVI in patients with PAF, 
with substantial parasympathetic withdrawal 
immediately after ablation and its gradual recov‑
ery in the next months. A persistent HRV atten‑
uation within the first 12 months after ablation 
for AF was a marker of the long ‑term procedural 
success and freedom from AF. A higher preabla‑
tion SDNN value potentially identified optimal 
candidates for CPVI, but this will require pro‑
spective validation. Conversely, an SDNN re‑
duction of 25 ms or less at 3 months after CPVI 
was a reliable predictor of a subsequent AF re‑
lapse. Preprocedural and follow ‑up HRV analy‑
ses could improve the prediction of LRAF in pa‑
tients with AF undergoing CPVI and, therefore, 
complement other clinical predictors of LRAF, 
such as ERAF.
